Involvement of the Toll-like receptor 4 pathway and use of TNF-α antagonists for treatment of the mucopolysaccharidoses

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 1, 2010, Pages 222-227

  Simonaro, Calogera M ^a   Ge, Yi ^a   Eliyahu, Efrat ^a   He, Xingxuan ^a   Jepsen, Karl J ^a   Schuchman, Edward H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bone and joint disease; Glycosaminoglycans; Growth plate; Inflammation

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STAT1 PROTEIN; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTHROPATHY; ARTICLE; CARTILAGE CELL; CONTROLLED STUDY; DRUG TARGETING; FACE; FEMUR; FIBROBLAST; GROWTH PLATE; HISTOLOGY; KNOCKOUT MOUSE; MALE; MAROTEAUX LAMY SYNDROME; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNOVIOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BONE AND BONES; HUMANS; MALE; MICE; MICE, KNOCKOUT; MUCOPOLYSACCHARIDOSES; RATS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; X-RAY MICROTOMOGRAPHY;

ANIMALIA; MUS; RATTUS;

EID: 76249093889     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0912937107     Document Type: Article

References (41)

1. Neufeld EF, Meunzer J (2001) The mucopolysaccharidoses. Metabolic and Molecular Basis of Inherited Disease, eds Scriver CR, Beaudet Al, Sly WS, Valle D (McGraw-Hill, New York), pp 3421-3452.
2. Clarke LA (2008) The mucopolysaccharidoses: A success of molecular medicine. Expert Rev Mol Med 10:e1.
3. Simonaro CM, Haskins ME, Schuchman EH (2001) Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: A possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 81:1319-1328.
4. Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH (2005) Joint and bone disease in mucopolysaccharidoses VI and VII: Identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 57:701-707.
5. Simonaro CM, et al. (2008) Mechanism of glycosaminoglycan-mediated bone and joint disease: Implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 172:112-122.
6. Ausseil J, et al. (2008) Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One 3:e2296.
7. Metcalf JA, Zhang Y, Hilton MJ, Long F, Ponder KP (2009) Mechanism of shortened bones in mucopolysaccharidosis VII. Mol Genet Metab 97:202-211.
8. Tessitore A, Pirozzi M, Auricchio A (2009) Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI. PathoGenetics 2:4.
9. Triantafilou M, Triantafilou K (2002) Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 23:301-304.
10. Hoshino K, et al. (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol 162:3749-3752.
11. Taylor KR, et al. (2007) Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 282:18265-18275.
12. Xia Y, Yamagata K, Krukoff TL (2006) Differential expression of the CD14/TLR4 complex and inflammatory signaling molecules following i.c.v. administration of LPS. Brain Res 1095:85-95.
13. Vogler C, et al. (1999) Enzyme replacement in murine mucopolysaccharidosis type VII: Neuronal and glial response to β-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res 45:838-844.
14. Sly WS (2004) Enzyme replacement therapy for lysosomal storage disorders: Successful transition from concept to clinical practice. Mo Med 101:100-104.
15. Rohrbach M, Clarke JT (2007) Treatment of lysosomal storage disorders: Progress with enzyme replacement therapy. Drugs 67:2697-2716.
16. Settembre C, Fraldi A, Rubinsztein DC, Ballabio A (2008) Lysosomal storage diseases as disorders of autophagy. Autophagy 4:113-114.
17. Raben N, Shea L, Hill V, Plotz P (2009) Monitoring autophagy in lysosomal storage disorders. Methods Enzymol 453:417-449.
18. Scherz-Shouval R, et al. (2007) Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 26:1749-1760.
19. Srinivas V, Bohensky J, Zahm AM, Shapiro IM (2009) Autophagy in mineralizing tissues: Microenvironmental perspectives. Cell Cycle 8:391-393.
20. Klionsky DJ, Cuervo AM, Seglen PO (2007) Methods for monitoring autophagy from yeast to human. Autophagy 3:181-206.
21. Ahmed Z, Archer JR, Brown RA (1995) Cell proliferation within the growth plate of the tich mouse. Bone 16 (4, Suppl):305S-310S.
22. Walker JG, et al. (2006) Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: Unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 65:149-156.
23. Hu X, Chen J, Wang L, Ivashkiv LB (2007) Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol 82:237-243.
24. Monari C, et al. (2009) A microbial polysaccharide reduces the severity of rheumatoid arthritis by influencing Th17 differentiation and proinflammatory cytokines production. J Immunol 183:191-200.
25. Richard M, Arfi A, Rhinn H, Gandolphe C, Scherman D (2008) Identification of new markers for neurodegeneration process in the mouse model of Sly disease as revealed by expression profiling of selected genes. J Neurosci Res 86:3285-3294.
26. Weaver AL (2004) Efficacy and safety of the anti-TNF biologic agents. Mod Rheumatol 14:101-112.
27. Strand V, Singh JA (2007) Improved health-related quality of life with effective disease-modifying antirheumatic drugs: Evidence from randomized controlled trials. Am J Manag Care 13 (Suppl 9):S237-S251.
28. Krzysiek R, et al. French Ankylosing Spondylitis Infliximab Network (2009) Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study. Arthritis Rheum 61:569-576.
29. Laharie D, et al. (2009) The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders. Aliment Pharmacol Ther 29: 1240-1248.
30. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89: 9784-9788.
31. Boettger MK, et al. (2008) Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: Evidence of a neuronal target. Arthritis Rheum 58:2368-2378.
32. Nagasawa H, Kameda H, Sekiguchi N, Amano K, Takeuchi T (2009) Improvement of the HAQ score by infliximab treatment in patients with RA: Its association with disease activity and joint destruction. Mod Rheumatol 19:166-172.
33. van der Kooij SM, et al. (2009) Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum 61:4-12.
34. Yavropoulou MP, Yovos JG (2008) Osteoclastogenesis-Current knowledge and future perspectives. J Musculoskelet Neuronal Interact 8:204-216.
35. Sands MS, Birkenmeier EH (1993) A single-base-pair deletion in the betaglucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII. Proc Natl Acad Sci USA 90:6567-6571.
36. Poltorak A, et al. (2001) A point mutation in the IL-12R beta 2 gene underlies the IL-12 unresponsiveness of Lps-defective C57BL/10ScCr mice. J Immunol 167:2106-2111.
37. Poltorak A, et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282:2085-2088.
38. Yoshida M, Noguchi J, Ikadai H, Takahashi M, Nagase S (1993) Arylsulfatase Bdeficient mucopolysaccharidosis in rats. J Clin Invest 91:1099-1104.
39. Kunieda T, et al. (1995) Mucopolysaccharidosis type VI in rats: Isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, and identification of the mutation. Genomics 29:582-587.
40. He X, Chen F, Gatt S, Schuchman EH (2001) An enzymatic assay for quantifying sphingomyelin in tissues and plasma from humans and mice with Niemann-Pick disease. Anal Biochem 293:204-211.
41. He X, Huang CL, Schuchman EH (2009) Quantitative analysis of sphingosine-1-phosphate by HPLC after napthalene-2,3-dicarboxaldehyde (NDA) derivatization. J Chromatogr, B Anal Technol Biomed Life Sci 877:983-990.